Table 5 The most frequent cs-DDIs among cancer patients, Uganda
cs-DDI | Frequency | Severity (category) | Evidence | Potential Adverse outcome |
|---|---|---|---|---|
Morphine + Metoclopramide | 48 | Moderate (C) | Fair | Drowsiness, somnolence (due to CNS depression enhancement by Metoclopramide) |
Cyclophosphamide + Doxorubicin | 28 | Major (C) | Fair | Increased risk of cardiotoxicity |
Taxanes + Platinum Analogues | 18 | Major (D) | Fair | Enhanced myelosuppression |
Dexamethasone + NSAIDS | 14 | Moderate (C) | Fair | Enhanced NSAID adverse effects (bleeding) |
Methotrexate + Proton Pump Inhibitors | 13 | Moderate (D) | Fair | Mucositis, Myalgias due to Methotrexate toxicity |
Fluorouracil + Folinic Acid | 12 | Major (C) | Fair | Increased concentrations of fluorouracil (fluorouracil toxicity (granulocytopenia, anaemia, thrombocytopenia, stomatitis, vomiting) |
Ondansetron + Domperidone | 11 | Moderate (D) | Fair | Increased risk of QT interval prolongation |
Capecitabine + Proton Pump Inhibitors | 11 | Moderate (C) | Fair | Decreased capecitabine effect |
Methotrexate + Mercaptopurine | 10 | Moderate (C) | Fair | Increased serum concentration of Mercaptopurine |
Dexamethasone + Antihyperglycemic agents | 10 | Moderate (C) | Fair | Hyperglycemia (decrease antihyperglycemic agents’ effect) |
Taxanes + Antihypertensives | 9 | Moderate (C) | Fair | Hypotension |
Morphine + Antihypertensives | 9 | Moderate (C) | Fair | Hypotension (enhanced hypotensive effect of morphine) |
Dexamethasone + Quinolones | 9 | Moderate (C) | Good | Increased risk for tendonitis and tendon rupture |
Dexamethasone + Fosaprepitant | 9 | Minor (D) | Good | Gastric bleeding (increased dexamethasone serum concentration) |
Ondansetron + Quinolones | 8 | Moderate (C) | Fair | Increased risk of QT interval prolongation |
Antihistamines + Metoclopramide | 7 | Moderate (C) | Fair | Drowsiness, somnolence (due to CNS depression enhancement by Metoclopramide) |